SCHEMBL3581992

SCHEMBL3581992

Nc1ccc(N)c(-c2ncc3cnn(-c4ccc5ccccc5c4)c3n2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
ALDH1A1 P00352 3/20 0.45
NPC1 O15118 1/20 0.45
POLB P06746 1/20 0.45
LMNA P02545 1/20 0.42
CYP3A4 P08684 3/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HSD17B10 Q99714 2/20 0.36
KDM4E B2RXH2 1/20 0.35
MAPK9 P45984 2/20 0.34
MAPK10 P53779 2/20 0.34
USP1 O94782 3/20 0.33
NPBWR1 P48145 1/20 0.33
ALOX15 P16050 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
HBB P68871 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1355247 0.83 GSK3B (0.46) RAB9AALDH1A1NPC1LMNACYP3A4
SCHEMBL1353450 0.83 XDH (0.46) RAB9ASMN1; SMN2ALDH1A1NPC1POLB
SCHEMBL3583981 0.81 ALDH1A1 (0.41) RAB9ASMN1; SMN2ALDH1A1NPC1POLB
SCHEMBL1356804 0.78 DHFR (0.36) RAB9ASMN1; SMN2ALDH1A1NPC1CYP3A4
SCHEMBL9926875 0.73 RAB9A (0.57) RAB9ASMN1; SMN2ALDH1A1NPC1POLB
SCHEMBL1355225 0.68 AURKA (0.41) RAB9AALDH1A1NPC1CYP3A4CYP2C9
SCHEMBL3587629 0.68 CYP19A1 (0.37)
SCHEMBL3581065 0.68 PIK3CD (0.36)
SCHEMBL3589889 0.66 OPRL1 (0.34)
SCHEMBL13790293 0.66 ALDH1A1 (0.69) RAB9ASMN1; SMN2ALDH1A1NPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190787-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC 2010-07-29 US claimed
EP-2108019-A2 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES Biogen Idec MA, Inc. (US) 2009-10-14 EP claimed
WO-2008094575-A2 1-H-PYRAZOLO(3,4B)PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES BIOGEN IDEC MA INC. (US) 2008-08-07 WO claimed
US-20100190787-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC 2010-07-29 US disclosed
EP-2108019-A2 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES Biogen Idec MA, Inc. (US) 2009-10-14 EP disclosed
WO-2008094575-A2 1-H-PYRAZOLO(3,4B)PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES BIOGEN IDEC MA INC. (US) 2008-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190787-A1 Modulators of Mitotic Kinases CDK1, BUB1, BUB1B RAB9A 2269/4885SMN1; SMN2 1911/4885ALDH1A1 4286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.